ProMIS Neurosciences, Inc.

NASDAQ:PMN

Biotechnology

Healthcare
$11.08 -0.14%

-$0.02 today

Market cap
$99.36M
Beta
-0.22
P/E (TTM)
-0.6
EPS (TTM)
-$4.62
52W Low $6.27High $27.40

Volume 0.13M

Average 0.07M

Returns on capital

ProMIS Neurosciences, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

3155.8%

avg 66635.3%

ROIC

3267.2%

avg -228592.4%

ROA

-432.6%

avg -13237.8%

Analysis

ROIC is currently the strongest return metric at 3267.2% versus its period average of -228592.4%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Neil K. Warma

Chief Executive Officer, President, Compliance Officer & DirectorCAD 604K63160.00K1.78%

Johanne Kaplan

Chief Development OfficerCAD 519.67K666.22K0.07%

Larry Douglas Altstiel

Chief Medical OfficerCAD 482K76165.00K1.84%

Eugene Williams

Co-Founder & ChairmanCAD 218.75K675.50K0.06%

Daniel E. Geffken

Chief Financial OfficerCAD 86.38K692.50K0.03%

Neil R. Cashman

Co-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director—74——

Dennis Chen

Head of Manufacturing & Senior Consultant————

David Wishart

Chief Physics Officer————

Compensation is shown in the reported currency; data updated Sep 29, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 5, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

9

$18.83M

Sells

0

$0.00

Net Transaction Value

+$18.83M

Net buying

Most Active

Williams Eugene

4 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Aug 5, 26

Kaplan Johanne

Direct

Buy$30.3K
Apr 22, 26

Kirwin Patrick D.

Indirect

Buy$45.3K
Mar 5, 26

Williams Eugene

Direct

Buy$48.8K
Mar 4, 26

Williams Eugene

Direct

Buy$48K
Mar 3, 26

Williams Eugene

Direct

Buy$21.9K
Mar 2, 26

Williams Eugene

Direct

Buy$22.5K
Feb 19, 26

Kaplan Johanne

Direct

Buy$25K
Feb 3, 26

ABG Management Ltd.

Indirect

Buy$8.5M
Feb 3, 26

ABG Management Ltd.

Indirect

Buy$10.1M

Summary

Insiders reported 9 buys worth $18.83M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $18.83M. Williams Eugene was the most active insider with 4 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A —
RevenueN/AN/AN/A
N/A —
Net IncomeN/AN/AN/A
N/A —
EBITN/AN/AN/A
N/A —

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does ProMIS Neurosciences, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about PMN's management, answered from reported figures.

Who manages PMN?

ProMIS Neurosciences, Inc. (PMN) lists 8 active executives. The top listed executive is Neil R. Cashman, Co-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director.

Are PMN insiders buying or selling?

Recent insider activity shows net buying of $60.73M.